...
首页> 外文期刊>Molecular pharmacology. >High-affinity binding of peptide agonists to the human B1 bradykinin receptor depends on interaction between the peptide N-terminal L-lysine and the fourth extracellular domain of the receptor.
【24h】

High-affinity binding of peptide agonists to the human B1 bradykinin receptor depends on interaction between the peptide N-terminal L-lysine and the fourth extracellular domain of the receptor.

机译:肽激动剂与人B1缓激肽受体的高亲和力结合取决于肽N端L-赖氨酸与受体第四胞外域之间的相互作用。

获取原文
获取原文并翻译 | 示例

摘要

The aim of this study was to identify the location of the N terminus of peptide agonist ligands when bound to the human B1 bradykinin (BK) receptor. To reach this aim, we exploited the fact that high-affinity binding of kinin peptides to the human B1 receptor subtype requires a peptide N-terminal L-Lys, whereas high-affinity binding to the B2 receptor subtype does not require this residue. This was done by comparing the affinities of BK, a B2 receptor-selective peptide, and kallidin or Lys-BK, a less receptor-selective peptide, for chimeric proteins in which each B1 receptor domain had been substituted in the human B2 receptor and expressed in HEK293 cells. Individual substitution of transmembrane domains 1-7 (TM-I-VII) and extracellular domains 1-4 (EC-I-IV) of the B1 receptor in the B2 receptor influenced the affinities of BK and Lys-BK approximately equally. In contrast, substitution of B1 EC-IV dramatically reduced the affinity and potency of BK, whereas these parameters for Lys-BK were essentially unaltered. Substitution of either the N- or C-terminal half of B1 EC-IV in the B2 receptor only had a limited effect on the peptide binding constants, indicating the involvement of multiple residues throughout this domain. Complementary mutations of the N-terminal residue in Lys-BK revealed that both the positive charge and the proper spatial orientation of this residue were required for interaction with B1 EC-IV. Thus, the N-terminal residue of peptide agonists when bound to the human B1 receptor is positioned extracellularly and interacts with EC-IV.
机译:这项研究的目的是确定与人B1缓激肽(BK)受体结合后肽激动剂配体N末端的位置。为了达到这个目的,我们利用了激肽肽与人B1受体亚型的高亲和力结合需要肽N端L-Lys的事实,而与B2受体亚型的高亲和力结合则不需要此残基。这是通过比较BK(一种B2受体选择性肽)和kallidin或Lys-BK(一种受体选择性较低的肽)对其中每个B1受体结构域已被人B2受体取代并表达的嵌合蛋白的亲和力来完成的在HEK293细胞中。 B2受体中B1受体的跨膜结构域1-7(TM-I-VII)和胞外结构域1-4(EC-1-IV)的个体替代大致相同地影响BK和Lys-BK的亲和力。相反,B1 EC-IV的取代显着降低了BK的亲和力和效力,而Lys-BK的这些参数基本上未发生变化。 B2受体中B1 EC-IV的N端或C端一半的取代仅对肽结合常数具有有限的影响,表明整个结构域中涉及多个残基。 Lys-BK中N末端残基的互补突变表明,与B1 EC-IV相互作用需要该残基的正电荷和正确的空间取向。因此,当与人B1受体结合时,肽激动剂的N-末端残基位于细胞外并与EC-IV相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号